• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Banff Ⅱ型和Ⅲ型急性细胞性排斥反应而无肾小管间质性浸润的移植肾的组织病理学和临床特征。

Histopathological and clinical findings in renal transplants with Banff type II and III acute cellular rejection without tubulointerstitial infiltrates.

机构信息

Institute of Pathology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany.

出版信息

Virchows Arch. 2014 Feb;464(2):203-11. doi: 10.1007/s00428-013-1487-0. Epub 2013 Dec 28.

DOI:10.1007/s00428-013-1487-0
PMID:24374461
Abstract

According to the Banff guidelines for renal transplants, pure endothelialitis without any tubulointerstitial infiltrates (with the Banff components v ≥ 1, i0, t0) has to be called acute cellular rejection (ACR). The pathophysiology of this rare lesion abbreviated as v_only is currently unclear, as well as its clinical, serological, and prognostic implications. Therefore, we conducted this retrospective comparative study. We compared all 23 biopsies with v_only from Hannover Medical School between 2003 and 2010 with 23 matched biopsies with the Banff components v ≥ 1, i ≥ 1, and t ≥ 1 (v_plus) and 23 biopsies with v0, i0, and t0 (v0i0t0). Serological (available in 10, 11, and 14 patients, respectively), histological, and clinical data were compared. Of all biopsies, 0.4 % had findings of v_only. v_only, v_plus, and v0i0t0 only showed minimal differences in the Banff components apart from the cohort-defining components. Endothelialitis in v_only more frequently involved the arcuate arteries than the smaller preglomerular vessels compared to v_plus and vice versa. Combining histopathological data and serological data, v_only more frequently showed criteria for acute humoral rejection than v0i0t0 (albeit not persistent after the Bonferroni-Holm correction in pairwise comparisons), while there was no difference between v_only and v_plus. No difference could be demonstrated regarding clinical presentation at biopsy or outcome. Our results show minimal differences regarding clinical presentation, outcome, and histological features between v_only and v_plus. Patients with v_only should be thoroughly investigated for evidence of acute humoral rejection.

摘要

根据 Banff 肾脏移植指南,单纯的血管内皮炎而无任何肾小管间质浸润(Banff 成分 v≥1,i0,t0)必须称为急性细胞排斥反应(ACR)。这种简写为 v-only 的罕见病变的发病机制目前尚不清楚,其临床、血清学和预后意义也不清楚。因此,我们进行了这项回顾性比较研究。我们比较了 2003 年至 2010 年间汉诺威医学院的 23 例 v-only 活检与 23 例 Banff 成分 v≥1、i≥1 和 t≥1(v_plus)及 23 例 v0、i0 和 t0(v0i0t0)的匹配活检。比较了血清学(分别在 10、11 和 14 例患者中可用)、组织学和临床数据。所有活检中,0.4%有 v-only 表现。除了队列定义成分外,v-only、v_plus 和 v0i0t0 在 Banff 成分上仅显示出微小差异。与 v_plus 相比,v-only 中的血管内皮炎更频繁地累及弓状动脉而不是较小的肾小球前血管,反之亦然。将组织病理学数据和血清学数据相结合,v_only 比 v0i0t0 更频繁地显示急性体液排斥反应的标准(尽管在两两比较的 Bonferroni-Holm 校正后没有持续存在),而 v_only 与 v_plus 之间没有差异。在活检时的临床表现或结果方面没有差异。我们的结果表明,v_only 和 v_plus 之间在临床表现、结果和组织学特征方面差异极小。v_only 患者应彻底检查急性体液排斥反应的证据。

相似文献

1
Histopathological and clinical findings in renal transplants with Banff type II and III acute cellular rejection without tubulointerstitial infiltrates.Banff Ⅱ型和Ⅲ型急性细胞性排斥反应而无肾小管间质性浸润的移植肾的组织病理学和临床特征。
Virchows Arch. 2014 Feb;464(2):203-11. doi: 10.1007/s00428-013-1487-0. Epub 2013 Dec 28.
2
An evaluation of the Banff classification of early renal allograft biopsies and correlation with outcome.早期肾移植活检的Banff分类评估及其与预后的相关性。
Nephrol Dial Transplant. 1999 Oct;14(10):2364-9. doi: 10.1093/ndt/14.10.2364.
3
The clinical and pathologic implications of plasmacytic infiltrates in percutaneous renal allograft biopsies.经皮肾移植活检中浆细胞浸润的临床及病理意义
Hum Pathol. 2001 Feb;32(2):205-15. doi: 10.1053/hupa.2001.21574.
4
Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification.肾移植中的急性体液排斥反应:II. 形态学、免疫病理学及病理分类
J Am Soc Nephrol. 2002 Mar;13(3):779-787. doi: 10.1681/ASN.V133779.
5
Predictors of renal transplant histology at three months.肾移植术后三个月组织学的预测因素
Transplantation. 1999 May 15;67(9):1222-30. doi: 10.1097/00007890-199905150-00005.
6
The Banff 97 working classification of renal allograft pathology.肾移植病理的班夫97工作分类法。
Kidney Int. 1999 Feb;55(2):713-23. doi: 10.1046/j.1523-1755.1999.00299.x.
7
Arcuate and interlobular phlebitis in renal allografts.同种异体肾移植中的弓形静脉炎和小叶间静脉炎。
Hum Pathol. 2001 Dec;32(12):1388-91. doi: 10.1053/hupa.2001.29669.
8
The severity of acute cellular rejection defined by Banff classification is associated with kidney allograft outcomes.Banff 分类定义的急性细胞排斥反应的严重程度与肾移植结局相关。
Transplantation. 2014 Jun 15;97(11):1146-54. doi: 10.1097/01.TP.0000441094.32217.05.
9
Banff criteria as predictors of outcome following acute renal allograft rejection.作为急性肾移植排斥反应后预后预测指标的班夫标准。
Nephrol Dial Transplant. 1999 Jul;14(7):1692-7. doi: 10.1093/ndt/14.7.1692.
10
Acute cellular rejection with isolated v-lesions is not associated with more favorable outcomes than vascular rejection with more tubulointerstitial inflammations.伴有孤立性血管病变的急性细胞性排斥反应与伴有更多肾小管间质炎症的血管性排斥反应相比,其预后并不更好。
Clin Transplant. 2014 Apr;28(4):410-8. doi: 10.1111/ctr.12333. Epub 2014 Mar 11.

引用本文的文献

1
Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation.利妥昔单抗与肾移植后晚期抗体介导排斥反应的监测策略
Transplant Direct. 2017 Oct 27;3(12):e227. doi: 10.1097/TXD.0000000000000746. eCollection 2017 Dec.
2
Current status of pediatric renal transplant pathology.小儿肾移植病理学的现状
Pediatr Nephrol. 2017 Mar;32(3):425-437. doi: 10.1007/s00467-016-3381-x. Epub 2016 May 24.
3
Proteomics for rejection diagnosis in renal transplant patients: Where are we now?蛋白质组学在肾移植患者排斥反应诊断中的应用:我们目前的进展如何?

本文引用的文献

1
Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: The INTERCOM study.微阵列诊断肾移植中 T 细胞介导排斥反应的潜在影响:INTERCOM 研究。
Am J Transplant. 2013 Sep;13(9):2352-63. doi: 10.1111/ajt.12387. Epub 2013 Aug 5.
2
Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies.人类肾移植活检中 T 细胞介导排斥反应的分子诊断。
Am J Transplant. 2013 Mar;13(3):645-55. doi: 10.1111/ajt.12079. Epub 2013 Jan 28.
3
Antibody-mediated vascular rejection of kidney allografts: a population-based study.
World J Transplant. 2016 Mar 24;6(1):28-41. doi: 10.5500/wjt.v6.i1.28.
4
Reassessing the Significance of Intimal Arteritis in Kidney Transplant Biopsy Specimens.重新评估肾移植活检标本中内膜动脉炎的意义
J Am Soc Nephrol. 2015 Dec;26(12):3190-8. doi: 10.1681/ASN.2014111064. Epub 2015 Apr 27.
抗体介导的肾移植血管排斥反应:一项基于人群的研究。
Lancet. 2013 Jan 26;381(9863):313-9. doi: 10.1016/S0140-6736(12)61265-3. Epub 2012 Nov 23.
4
Acute vascular rejection after renal transplantation and isolated v-lesion.肾移植后急性血管排斥反应和孤立性 v 病变。
Clin Transplant. 2012 Jul;26 Suppl 24:2-8. doi: 10.1111/j.1399-0012.2012.01673.x.
5
Banff 2011 Meeting report: new concepts in antibody-mediated rejection.班夫 2011 年会报告:抗体介导排斥反应的新概念。
Am J Transplant. 2012 Mar;12(3):563-70. doi: 10.1111/j.1600-6143.2011.03926.x. Epub 2012 Feb 2.
6
The nature of biopsies with "borderline rejection" and prospects for eliminating this category.“临界排斥”活检的性质和消除这一范畴的前景。
Am J Transplant. 2012 Jan;12(1):191-201. doi: 10.1111/j.1600-6143.2011.03784.x. Epub 2011 Oct 12.
7
Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation.供者特异性抗体加速肾移植后的动脉硬化。
J Am Soc Nephrol. 2011 May;22(5):975-83. doi: 10.1681/ASN.2010070777. Epub 2011 Apr 14.
8
Why rejections are not biopsy proven: frequency and reasons.为何排斥反应未经活检证实:频率及原因
Transplant Proc. 2010 Dec;42(10):4509-12. doi: 10.1016/j.transproceed.2010.09.158.
9
Defining the canonical form of T-cell-mediated rejection in human kidney transplants.定义人类肾移植中 T 细胞介导排斥反应的典型形式。
Am J Transplant. 2010 Apr;10(4):810-820. doi: 10.1111/j.1600-6143.2009.03007.x. Epub 2010 Feb 3.
10
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups.Banff '09 会议报告:抗体介导的移植物损伤和 Banff 工作组的实施。
Am J Transplant. 2010 Mar;10(3):464-71. doi: 10.1111/j.1600-6143.2009.02987.x. Epub 2010 Jan 29.